|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
22.09.25 - 07:03
|
Ipsen′s LANTIC Phase II in aesthetics delivers a first-in-class, differentiated long-acting clinical profile for IPN10200, enabling the initiation of Phase III (GlobeNewswire EN)
|
|
|
PARIS, FRANCE, 22 September 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced the first aesthetic data (n=183) for glabellar lines with internally developed IPN10200, following Stage 1 of the multi-stage, ongoing Phase II LANTIC trial. Patients treated with IPN10200 showed a statistically significant improvement in response at Week 4 vs placebo (primary endpoint). A longer duration of effect was also observed with a substantial majority of patients experiencing a clinically significant response at Week 24 compared with placebo and Dysport, defined as a score of “none” or “mild”. IPN10200 continued to show a greater response in line severity vs Dysport at Week 36. In this trial Dysport was shown to perform consistently with its profile....
|
|
|
|
|
19.09.25 - 14:03
|
Bylvay® (odevixibat) approved in Japan for rare liver disease PFIC (GlobeNewswire EN)
|
|
|
Paris, France – 19 September 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted regulatory approval for Bylvay® (odevixibat) for the treatment of pruritus associated with progressive familial intrahepatic cholestasis (PFIC). PFIC is a group of rare genetic disorders in which bile acid accumulates in the liver, leading to progressive liver damage and potentially liver failure. The condition severely impacts quality of life through debilitating symptoms such as severe itching (pruritus), caused by the bile accumulation in the liver and bloodstream, which can cause skin mutilation, sleep disruption, irritability, and impaired cognitive and social development....
|
|
|
|
|
12.09.25 - 07:33
|
Medincell Announces the Appointment of Dr. Sharon Mates, Dr. Charles Kunsch, and Dr. Pascal Touchon to Its Board of Directors (Business Wire)
|
|
|
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News:
Medincell (Paris:MEDCL) General Assembly held on September 11, 2025, has approved the appointments of three new independent board members: Dr Sharon Mates, Dr. Charles Kunsch, and Dr. Pascal Touchon.
Dr. Sharon Mates, PhD, is the co-founder and former Chair and CEO of Intra-Cellular Therapies, a CNS-focused biotech that developed the successful drug CAPLYTA®, acquired by Johnson & Johnson for $14.6 billion in April 2025.
Dr. Charles Kunsch, PhD, is a seasoned life sciences executive with over 30 years of experience, including as former Managing Director at AbbVie Ventures, where he led investments in pioneering biotech companies.
Dr. Pascal Touchon, DVM, has over 40 years of international leadership in the biopharmaceutical industry, including key roles at Novartis Oncology and Atara Biotherapeutics and current board positions at Ipsen, CDR-Life, RoslinCT, Catalym and Xylocor.
Philippe Guy, Chairman of Medincell's Board, said: “With the election o...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
